$ETRM, Analysts Advise About EnteroMedics Inc.

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
$ETRM,


Analysts Advise About EnteroMedics Inc. (NASDAQ:ETRM)
By
Francis Lewis -
November 23, 2016
82.png

EnteroMedics Inc. (NASDAQ:ETRM) stock is presently standing at about $0.09 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 2 analysts covering the company is $1.10, which suggests the stock could still rise over 92 percent. The highest analyst price target is $2.00, which implies a rally of -2022 percent. And a quick view of analyst notes show that 1 are rating the stock a buy while 0 rate ETRM a strong buy. There are 1 equity research firms advocating a Hold and 0 consider it Sell.

ROTH Capital analysts provided their view on EnteroMedics Inc. (NASDAQ:ETRM) recently. The rating firm issued a Neutral rating to this company in a research note released on Jun 09, 2016. Northland Securities analysts disclosed their opinion on EnteroMedics Inc. (NASDAQ:ETRM) recently. The rating firm gave a Outperform rating to this stock in a research note published on Jun 29, 2012. According to a research note disclosed on Jan 09, 2009, analysts at Argus have lowered their rating on these shares from Hold to Sell.

EnteroMedics Inc. (NASDAQ:ETRM) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its SVP, Ops & Bus Dev DeLange Peter M. Purchased 20,000 company shares for $11000, in a transaction on 2016-06-03. Following the transaction, the SVP, Ops & Bus Dev is left with a stake of 11 shares, currently valued at $1. Meanwhile, CEO GLADNEY DAN W purchased 50,000 shares worth $135000, through a transaction dated 2015-11-12. Following the completion of the transaction, the insider is left with a stake of 50,000 shares, amounting $4500. ETRM Chrmn, Pres & CEO KNUDSON MARK B also purchased 20,667 shares, at a stock price of $2.4. This transaction occurred on 2015-11-12 totals $49000.6. After this transaction, the insider’s stake stands at 45,011 shares, with a market value of $4051.

Executives hold 0.99 percent of the stock. Kevin G. Douglas is one of the biggest insider owners in EnteroMedics Inc. (NASDAQ:ETRM), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 3,010,852 shares which have current market value of around $270976.68.Mr. Dan W. Gladney is another major inside shareholder in the company. The insider owns 134,745 shares as of 0.12%, currently worth $12127.05. Dr. Mark B. Knudson, PhD is ranked as third insider holder of the stock. This insider holds 40,867 shares with a market value around $3678.03 as of recent close.

EnteroMedics Inc. (NASDAQ:ETRM) Earnings Outlook

In EnteroMedics Inc. (NASDAQ:ETRM)’s latest quarter, EPS moved to $-0.17 from $-0.49 in preceding quarter and revenues reached at $0.30M compared to $0.28M. Analysts had expected EnteroMedics Inc. (NASDAQ:ETRM) to post net income of about $-0.50 per share on $0.34M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in in the range of $-0.50 to $-0.38. That is compared with the $-0.95 in EPS it reported during the same period a year ago.
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 21

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 169

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 33

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 176

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 229

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 81

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading

Top 5 Most Recently Viewed Articles

Hepsor Latvia OÜ Expands Footprint with Strategic Acquisition

Updated Category News Views 169

Hepsor Latvia OÜ’s Bold Move in Real Estate Development Hepsor Latvia OÜ, a proud subsidiary of Hepsor AS, has made waves in the Latvian real estate market with its recent acquisition of a 100% stake in Starta 17 SIA. This pivotal move highlights Hepsor's commitment to strengthening its position in the region. Details of the Acquisition The acquisition involves Starta...

Continue Reading
Euro Sun Mining Advances in Sustainable Copper-Gold Mining

Updated Category News Views 181

Euro Sun Mining's Strategic Advancements Euro Sun Mining (OTC: CPNFF) is making significant strides to propel its Rovina/Colnic copper and gold porphyry open-pit mining project in Romania. This movement is aligned with the European Union's initiatives to bolster critical mineral supplies within the continent. Recent developments highlight an updated Definitive Feasibility...

Continue Reading
Kevin Olsavsky Joins Michael Baker International Team

Updated Category News Views 123

Welcoming Kevin Olsavsky to Michael Baker International Michael Baker International, a well-respected global leader in engineering, consulting, and technology services, has welcomed Kevin Olsavsky as the new Mission Critical and Data Center Market Sector Leader. As a seasoned industry professional, Mr. Olsavsky's expertise will significantly boost the firm’s...

Continue Reading
AJOVY® Shows Long-Term Effectiveness Against Migraines

Updated Category News Views 328

Insights from PEARL Study on AJOVY® for Migraine Prevention Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has unveiled insightful findings from the final analysis of its PEARL Phase 4 migraine prevention study. This pan-European clinical trial has clearly demonstrated that AJOVY (fremanezumab), a monoclonal antibody designed to inhibit calcitonin gene-related...

Continue Reading
Datavault AI Unveils Ambitious Plans for Future Growth

Updated Category News Views 285

Datavault AI's Vision for Expansive Growth Datavault AI Inc. (NASDAQ: DVLT), a trailblazer in AI-driven solutions for data monetization and asset tokenization, is forging ahead with innovative strategies that promise an exciting future. The company has recently announced its plans to integrate four groundbreaking independent data exchanges, which are projected to...

Continue Reading